AstraZeneca Targets Ambitious $80B In Total Revenue By 2030 Through Pipeline Expansion

Tuesday, AstraZeneca Plc AZN announced its ambitious plan to increase its total revenue to $80 billion by 2030, a significant rise from $45.8 billion in 2023. 

Substantial expansion in its oncology, biopharmaceuticals, and rare disease portfolios and introducing 20 new medicines by the decade’s end will fuel the growth. 

To sustain growth beyond 2030, the company will invest in transformative technologies and platforms that will shape the future of medicine.

AstraZeneca will uphold its strategic focus on R&D while enhancing productivity across the organization. 

This approach aims to drive operating leverage, supporting the goal of achieving a mid-30s percentage core operating margin by 2026. 

The evolving portfolio will influence the core operating margin post-2026, with the aim of maintaining it at least in the mid-30s percentage range.

Pascal Soriot, CEO, said, “Today, AstraZeneca announces a new era of growth. In 2023, we delivered the ambitious $45 billion revenue goal set a decade ago. With the exciting growth of our innovative pipeline, which has the potential to transform millions of lives, we are now aiming for $80 billion by 2030. We are planning to launch 20 new medicines by 2030, many with the potential to generate more than $5 billion in peak-year revenues…”

AstraZeneca said it would continue to invest in new technologies and platforms that will “shape the future of medicine” beyond 2030.

“We think this is more than good enough to keep (AstraZeneca) shares working as we head to the main event today,” Reuters noted, citing a Barclays analyst.

“At today’s meeting, we expect the company to flesh out which pipeline assets have blockbuster and multi-blockbuster peak sales potential, as well as the supportive clinical data and market sizing,” Reuters noted, quoting a JP Morgan analyst.

Reuters, citing Jefferies, highlighted that the revenue target of $80 billion was widely expected, adding that major new drug catalysts will be “somewhat scarce” until 2025.

Reuters noted that analysts at JP Morgan said the ambition would imply an upside of about 20% to the company’s 2030 consensus of $66.8 billion.

Price Action: At last check Tuesday, AZN shares were up 1.23% at $78.07 during the premarket session.

Photo via Wikimedia Commons